Acr, FDA and endometrial cancer

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay
The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 OncoSignature assay designed to detect endometrial cancer patients who can benefit from the treatment of ACR-368.
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status
We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to take a look at where Acrivon Therapeutics, Inc. (NASDAQ:ACRV) stands against other AI news and ratings investors are keeping their eye on.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing,
Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification
Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment.
ACR-368 OncoSignature assay gains FDA breakthrough status
Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that its ACR-368 OncoSignature assay has received Breakthrough Device designation from the U.
Acrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature Assay
Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food
American Association of Individual Investors2d
Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Up 17.94%
Acrivon Therapeutics, Inc.’s ACRV share price has surged by 17.94%, which has investors questioning if this is right time to ...
China Universal Asset Management Co. Ltd. Takes Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
China Universal Asset Management Co. Ltd. bought a new stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) during the fourth quarter, according to the company in its most recent 13F filing ...
Morningstar7d
Acrivon Therapeutics Inc ACRV
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance9d
Acrivon Therapeutics, Inc. (ACRV) stock forecast and price target
Find the latest Acrivon Therapeutics, Inc. ACRV analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
ETF Daily News13d
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus Price Target from Analysts
Acrivon Therapeutics has a 12 month low of $3.19 and a 12 month high of $11.90. The company has a market capitalization of $169.71 million, a P/E ratio of -2.02 and a beta of 0.77. Institutional ...
Acrivon Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (ACRV) with an Overweight rating without a price target The company has two ...